Cargando…
Identification of a dominant CD8(+) CTL epitope in the SARS-associated coronavirus 2 spike protein
Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, has been spreading throughout the world. To date, there are still no approved human vaccines for this disease. To develop an effective vaccine, the establishment of animal models for evaluating post-vaccination immune responses is n...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571903/ https://www.ncbi.nlm.nih.gov/pubmed/33164796 http://dx.doi.org/10.1016/j.vaccine.2020.10.039 |
_version_ | 1783597241594806272 |
---|---|
author | Muraoka, Daisuke Situo, Deng Sawada, Shin-ichi Akiyoshi, Kazunari Harada, Naozumi Ikeda, Hiroaki |
author_facet | Muraoka, Daisuke Situo, Deng Sawada, Shin-ichi Akiyoshi, Kazunari Harada, Naozumi Ikeda, Hiroaki |
author_sort | Muraoka, Daisuke |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, has been spreading throughout the world. To date, there are still no approved human vaccines for this disease. To develop an effective vaccine, the establishment of animal models for evaluating post-vaccination immune responses is necessary. In this study, we have identified a CTL epitope in the SARS-CoV-2 spike (S) protein that could be used to measure the cellular immune response against this protein. Potential predicted CTL epitopes of the SARS-CoV-2 S protein were investigated by immunizing BALB/c mice with a recombinant of the receptor-binding domain (RBD) of the S protein. Then, CD8(+) T cells specific for S-RBD were detected by stimulating with potential epitope peptides and then measuring the interferon-gamma production. Truncation of this peptide revealed that S-RBD-specific CD8(+) T cells recognized a H2-D(d)-restricted S(526–533) peptide. In conclusion, this animal model is suitable for evaluating the immunogenicity of SARS-CoV-2 vaccines. |
format | Online Article Text |
id | pubmed-7571903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75719032020-10-20 Identification of a dominant CD8(+) CTL epitope in the SARS-associated coronavirus 2 spike protein Muraoka, Daisuke Situo, Deng Sawada, Shin-ichi Akiyoshi, Kazunari Harada, Naozumi Ikeda, Hiroaki Vaccine Short Communication Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, has been spreading throughout the world. To date, there are still no approved human vaccines for this disease. To develop an effective vaccine, the establishment of animal models for evaluating post-vaccination immune responses is necessary. In this study, we have identified a CTL epitope in the SARS-CoV-2 spike (S) protein that could be used to measure the cellular immune response against this protein. Potential predicted CTL epitopes of the SARS-CoV-2 S protein were investigated by immunizing BALB/c mice with a recombinant of the receptor-binding domain (RBD) of the S protein. Then, CD8(+) T cells specific for S-RBD were detected by stimulating with potential epitope peptides and then measuring the interferon-gamma production. Truncation of this peptide revealed that S-RBD-specific CD8(+) T cells recognized a H2-D(d)-restricted S(526–533) peptide. In conclusion, this animal model is suitable for evaluating the immunogenicity of SARS-CoV-2 vaccines. Elsevier Ltd. 2020-11-17 2020-10-19 /pmc/articles/PMC7571903/ /pubmed/33164796 http://dx.doi.org/10.1016/j.vaccine.2020.10.039 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Muraoka, Daisuke Situo, Deng Sawada, Shin-ichi Akiyoshi, Kazunari Harada, Naozumi Ikeda, Hiroaki Identification of a dominant CD8(+) CTL epitope in the SARS-associated coronavirus 2 spike protein |
title | Identification of a dominant CD8(+) CTL epitope in the SARS-associated coronavirus 2 spike protein |
title_full | Identification of a dominant CD8(+) CTL epitope in the SARS-associated coronavirus 2 spike protein |
title_fullStr | Identification of a dominant CD8(+) CTL epitope in the SARS-associated coronavirus 2 spike protein |
title_full_unstemmed | Identification of a dominant CD8(+) CTL epitope in the SARS-associated coronavirus 2 spike protein |
title_short | Identification of a dominant CD8(+) CTL epitope in the SARS-associated coronavirus 2 spike protein |
title_sort | identification of a dominant cd8(+) ctl epitope in the sars-associated coronavirus 2 spike protein |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571903/ https://www.ncbi.nlm.nih.gov/pubmed/33164796 http://dx.doi.org/10.1016/j.vaccine.2020.10.039 |
work_keys_str_mv | AT muraokadaisuke identificationofadominantcd8ctlepitopeinthesarsassociatedcoronavirus2spikeprotein AT situodeng identificationofadominantcd8ctlepitopeinthesarsassociatedcoronavirus2spikeprotein AT sawadashinichi identificationofadominantcd8ctlepitopeinthesarsassociatedcoronavirus2spikeprotein AT akiyoshikazunari identificationofadominantcd8ctlepitopeinthesarsassociatedcoronavirus2spikeprotein AT haradanaozumi identificationofadominantcd8ctlepitopeinthesarsassociatedcoronavirus2spikeprotein AT ikedahiroaki identificationofadominantcd8ctlepitopeinthesarsassociatedcoronavirus2spikeprotein |